These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12482324)

  • 21. Ile115Leu mutation in the SRS1 region of an insect cytochrome P450 (CYP6B1) compromises substrate turnover via changes in a predicted product release channel.
    Wen Z; Baudry J; Berenbaum MR; Schuler MA
    Protein Eng Des Sel; 2005 Apr; 18(4):191-9. PubMed ID: 15837716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
    Hummel MA; Gannett PM; Aguilar JS; Tracy TS
    Biochemistry; 2004 Jun; 43(22):7207-14. PubMed ID: 15170358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.
    Guengerich FP; Hanna IH; Martin MV; Gillam EM
    Biochemistry; 2003 Feb; 42(5):1245-53. PubMed ID: 12564927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asp218 participates with Asp213 to bind a Ca2+ atom into the S1 subsite of aminopeptidase A: a key element for substrate specificity.
    Claperon C; Rozenfeld R; Iturrioz X; Inguimbert N; Okada M; Roques B; Maigret B; Llorens-Cortes C
    Biochem J; 2008 Nov; 416(1):37-46. PubMed ID: 18598240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crystal structure of human cytochrome P450 2C9 with bound warfarin.
    Williams PA; Cosme J; Ward A; Angove HC; Matak Vinković D; Jhoti H
    Nature; 2003 Jul; 424(6947):464-8. PubMed ID: 12861225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.
    Hanna IH; Kim MS; Guengerich FP
    Arch Biochem Biophys; 2001 Sep; 393(2):255-61. PubMed ID: 11556812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
    Liu KH; Kim MJ; Jung WM; Kang W; Cha IJ; Shin JG
    Drug Metab Dispos; 2005 Feb; 33(2):209-13. PubMed ID: 15537834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Asp174 and Asp175 as the key catalytic residues of human O-GlcNAcase by functional analysis of site-directed mutants.
    Cetinbaş N; Macauley MS; Stubbs KA; Drapala R; Vocadlo DJ
    Biochemistry; 2006 Mar; 45(11):3835-44. PubMed ID: 16533067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
    Zhou SF; Zhou ZW; Yang LP; Cai JP
    Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of recombinant cytochrome P450 2C9 activity with diclofenac by MEKC.
    Konecný J; Jurica J; Tomandl J; Glatz Z
    Electrophoresis; 2007 Apr; 28(8):1229-34. PubMed ID: 17377945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.
    Subramanian M; Low M; Locuson CW; Tracy TS
    Drug Metab Dispos; 2009 Aug; 37(8):1682-9. PubMed ID: 19448135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9.
    Peng CC; Rushmore T; Crouch GJ; Jones JP
    Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9.
    Zamora I; Afzelius L; Cruciani G
    J Med Chem; 2003 Jun; 46(12):2313-24. PubMed ID: 12773036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
    He SM; Zhou ZW; Li XT; Zhou SF
    Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution.
    Wester MR; Yano JK; Schoch GA; Yang C; Griffin KJ; Stout CD; Johnson EF
    J Biol Chem; 2004 Aug; 279(34):35630-7. PubMed ID: 15181000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.
    Subramanian M; Agrawal V; Sandee D; Tam HK; Miller WL; Tracy TS
    Pharmacogenet Genomics; 2012 Aug; 22(8):590-7. PubMed ID: 22547083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five crucial carboxyl residues of 1,2-alpha-mannosidase from Aspergillus saitoi (A. phoenicis), a food microorganism, are identified by site-directed mutagenesis.
    Fujita A; Yoshida T; Ichishima E
    Biochem Biophys Res Commun; 1997 Sep; 238(3):779-83. PubMed ID: 9325167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts.
    Rossato G; Ernst B; Smiesko M; Spreafico M; Vedani A
    ChemMedChem; 2010 Dec; 5(12):2088-101. PubMed ID: 21038340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of atypical kinetic behaviour of cytochrome P450 2C9 isoform with diclofenac at low substrate concentrations by sweeping-MEKC combination.
    Řemínek R; Glatz Z
    J Sep Sci; 2010 Oct; 33(20):3201-6. PubMed ID: 20848598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of ethanol on S-warfarin and diclofenac metabolism by recombinant human CYP2C9.1.
    Tatsumi A; Ikegami Y; Morii R; Sugiyama M; Kadobayashi M; Iwakawa S
    Biol Pharm Bull; 2009 Mar; 32(3):517-9. PubMed ID: 19252308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.